Imdelltra (tarlatamab-dlle) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
53 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imdelltra (tarlatamab-dlle) / Amgen
NCT06064500: Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Approved for marketing
3b
Japan, US, RoW
Tarlatamab, AMG 757
Amgen
Small Cell Lung Cancer
 
 
DeLLphi-305, NCT06211036 / 2023-505989-29-00: Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Active, not recruiting
3
563
Europe, Canada, Japan, US, RoW
Tarlatamab, AMG 757, Durvalumab
Amgen, Amgen Inc.
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
07/27
09/28
DeLLphi-304, NCT05740566 / 2022-502669-14-00: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Hourglass Nov 2025 - Nov 2025 : Anticipated approval in US
Active, not recruiting
3
509
Europe, Canada, Japan, US, RoW
Tarlatamab, AMG 757, Lurbinectedin, Topotecan, Amrubicin
Amgen, Amgen Inc
Small Cell Lung Cancer (SCLC)
01/25
03/28
DeLLphi-312, NCT07005128: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Recruiting
3
330
Europe, Japan, US, RoW
Tarlatamab, AMG 757, Imdelltra, Durvalumab, Carboplatin, Etoposide
Amgen, AstraZeneca
Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
01/29
07/29
TARLANEC, NCT06937905 / 2024-515948-23-00: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Recruiting
3
129
Europe
Standard of Care Chemotherapy, Tarlatamab
Intergroupe Francophone de Cancerologie Thoracique
Neuroendocrine Carcinoma
02/29
08/30
DeLLphi-306, NCT06117774 / 2023-506235-15-00: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Active, not recruiting
3
404
Europe, Japan, US, RoW
Tarlatamab, AMG 757, Placebo
Amgen, Amgen Inc.
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
04/30
04/30
20210004, 2022-502669-14-00: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304)

Active, not recruiting
2/3
199
Europe
DEXAMETHASONE, TOPOTECAN, ELECTROLYTES, SILTUXIMAB, TOCILIZUMAB, Tarlatamab
Amgen Inc., Amgen Inc
Small cell lung cancer (SCLC)
 
 
GCO-003 TARLANEC, 2024-515948-23-00: Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)

Recruiting
2/3
129
Europe
Tarlatamab, OXALIPLATINE VIATRIS 5 mg/ml, poudre pour solution pour perfusion, Dacarbazine "Lipomed", Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Temozolomide 100 mg hard capsules, OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Topotecan Accord Healthcare 4mg Powder for Concentrate for Solution for Infusion, IRINOTECAN VIATRIS 20 mg/ml, solution ? diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution ? diluer pour perfusion
Intergroupe Francophone De Cancerologie Thoracique
Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)
 
 
20240178, 2024-520050-38-00: Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)

Active, not recruiting
2/3
129
Europe
MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN
Amgen Inc.
Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.
 
 
20230016, 2023-506235-15-00: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited?Stage Small?Cell Lung Cancer (DeLLphi-306)

Recruiting
2/3
145
Europe
Tarlatamab, ELECTROLYTES , TOCILIZUMAB, VASOPRESSIN (ARGIPRESSIN) , DEXAMETHASONE, PARACETAMOL , SILTUXIMAB, PREDNISOLONE , Placebo for Tarlatamab (AMG-757)
Amgen Inc., Amgen Inc.
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
 
 
DeLLphi-301, NCT05060016 / 2021-002566-40: A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

Active, not recruiting
2
222
Europe, Japan, US, RoW
Tarlatamab
Amgen
Relapsed/Refractory Small Cell Lung Cancer
12/26
12/27
DeLLphi-307, NCT06502977: Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Active, not recruiting
2
32
RoW
Tarlatamab, AMG 757, IMDELLTRAâ„¢
Amgen
Extensive Stage Small Cell Lung Cancer
03/25
01/27
DeLLphi-309, NCT06745323 / 2024-516051-40-00: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Active, not recruiting
2
252
Europe, Japan, US, RoW
Tarlatamab, AMG 757
Amgen, Amgen Inc.
Small Cell Lung Cancer (SCLC)
02/29
02/29
NCT06788938: Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Recruiting
2
29
US
Tarlatamab treatment
Jonsson Comprehensive Cancer Center, Amgen
DLL3-expressing Tumors, Advanced Tumors
04/28
04/29
NCT06830694: Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Recruiting
2
50
RoW
Atezolizumab, Etoposide, Carboplatin, Tarlatamab
Se-Hoon Lee
Small Cell Carcinoma of Lung
03/27
06/27
TAURUS, NCT06816394: Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma

Not yet recruiting
2
32
RoW
Tarlatamab
National Taiwan University Hospital, Amgen
Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma
12/27
04/29
TIDAL, NCT07111507: A Study of Tarlatamab for People With Prostate Cancer

Recruiting
2
32
US
Tarlatamab
Memorial Sloan Kettering Cancer Center, Amgen
Metastatic Prostate Cancer
08/27
08/27
NCT06776250: Study of How Safe and Effective Tarlatamab is in Brain Cancers

Recruiting
2
44
Canada
Tarlatamab
University Health Network, Toronto, Amgen
Astrocytic Tumor, Oligodendroglial Tumor
03/28
03/28
DeLLight, NCT06893783: Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Recruiting
2
60
RoW
Tarlatamab, Delta-like ligand 3 (DLL3) Bispecific T-Cell Engager
Inkeun Park, Seoul National University Hospital, Severance Hospital, Samsung Medical Center
Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas, Neuroendocrine Carcinoma of Prostate
04/29
04/29
RAGNAR, NCT07061080 / 2024-514327-42-00: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

Recruiting
2
87
Europe
Tarlatamab, standard of care second-line chemotherapy (FOLFIRI)
Grupo Espanol de Tumores Neuroendocrinos, Amgen
Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin
12/28
12/28
T-BRAIN, NCT07402343 / 2025-522162-75-00: Tarlatamab for SCLC Brain Metastases

Not yet recruiting
2
34
Europe
Tarlatamab
Maastricht University Medical Center, The Netherlands Cancer Institute, Erasmus Medical Center, University Medical Center Groningen
Small Cell Lung Cancer, Brain Metastases, Adult
02/29
02/30
NCT07423585: Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Recruiting
2
39
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography, Echocardiography Test, EC, Echocardiography, Electronic Health Record Review, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration, Tarlatamab, AMG 757, AMG-757, AMG757, Anti-DLL3 x Anti-CD3 BiTE AMG 757, Bispecific T-cell Engager Antibody AMG 757, BiTE Antibody AMG 757, DLL3/CD3-directed Bispecific T-cell Engager Antibody AMG 757, Imdelltra, Tarlatamab-dlle
Asrar Alahmadi, Amgen
Extensive Stage Lung Small Cell Carcinoma
12/27
12/27
START-lung, NCT07203053 / 2025-522288-13-00: A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

Recruiting
2
48
Europe
Tarlatamab
ETOP IBCSG Partners Foundation, Amgen
Extensive Stage Lung Small Cell Cancer
10/29
10/29
MERLIN, NCT07242547 / 2024-515201-26-00: Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients

Recruiting
2
37
Europe
Tarlatamab, Imdelltra
Fundación GECP, Fundaci?n GECP
Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms
06/30
06/30
ChiCTR2500103532: Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects with Advanced Small Cell Lung Cancer after Two or More Prior Lines of Treatment (DeLLphi-307)

Completed
2
30
 
Tarlatamab
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology, Amgen Inc.&BeiGene(Beijing) CO, Ltd.（local agency）
Small Cell Lung Cancer (SCLC)
 
 
NCT07016230 / 2024-515847-47-00: Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Recruiting
2
40
Europe
Tarlatamab
Gustave Roussy, Cancer Campus, Grand Paris, Amgen
Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)
04/27
01/30
RABBIT, NCT06814496: Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Recruiting
1/2
30
US
Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy
University of Arizona, Amgen
Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
05/30
05/30
NCT07328490: Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Withdrawn
1/2
120
US
Tarlatamab, Sacituzumab Govitecan
National Cancer Institute (NCI)
Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
04/26
04/26
20200491, 2024-511837-37-00: A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC).

Active, not recruiting
1/2
113
Europe
Tarlatamab, TARLATAMAB, SILTUXIMAB
Amgen Inc., Amgen Inc.
Relapsed/Refractory Small Cell Lung Cancer
 
 
CSET 2024/4014, 2024-515847-47-00: Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), with biomarker analysis to characterize response/resistance (UNLOCK TARLATAMAB)

Recruiting
1/2
40
Europe
Tarlatamab
Institut Gustave Roussy, AMGEN
Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)
 
 
20240092, 2024-516051-40-00: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC

Active, not recruiting
1/2
60
Europe
Tarlatamab, SILTUXIMAB
Amgen Inc., Amgen Inc.
Small Cell Lung Cancer (SCLC)
 
 
2024-514327-42-00: RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab

Recruiting
1/2
87
Europe
Irinotec?n Hospira 20 mg/mL concentrado para soluci?n para perfusi?n EFG., Tarlatamab, Folinato c?lcico Altan 50 mg polvo para soluci?n inyectable EFG, Fluorouracilo Accord 50 mg/ml soluci?n inyectable o para perfusi?n EFG
Grupo Espanol De Tumores Neuroendocrinos
Advanced neuroendocrine carcinomas (NECs) of the digestive system or unknown primary origin.
 
 
AIO-TRK-0624, 2025-522437-65-00: A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung cancer with poor performance status (SPACE-T)

Recruiting
1/2
57
Europe
Tarlatamab
AIO-Studien gGmbH, AMGEN
small-cell lung cancer
 
 
2025-522162-75-00: A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer

Not yet recruiting
1/2
35
Europe
Tarlatamab
Academisch Ziekenhuis Maastricht, AMGEN
patients with asymptomatic active brain metastases from small cell lung cancer
 
 
MERLIN (GECP 24/02), 2024-515201-26-00: Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot receive both treatments at the same time.

Recruiting
1/2
37
Europe
Tarlatamab
Fundacion GECP, Fundaci?n GECP
Small cell lung cancer (SCLC)
 
 
ET23-040, 2023-510568-11-00: TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II trial aiming to assess the safety and clinical activity of Tarlatamab in combination with metronomic Temozolomide in adolescents and adults? patients with high grade brain tumors

Recruiting
1/2
450
Europe
TEMOZOLOMIDE , Tarlatamab
Centre Leon Berard, French NCI (INCA) and Fondation ARC
High grade brain tumors
 
 
TARLATEM, NCT07243470 / 2023-510568-11-00: Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Recruiting
1/2
70
Europe
Tarlatamab, Temozolomide (TMZ), Temodal
Centre Leon Berard, Amgen, National Cancer Institute, France
Glioma, CNS Tumor, Adult, CNS Tumor, Childhood
10/29
10/30
DeLLpro-300, NCT04702737 / 2024-513316-10-00: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

Completed
1
41
Europe, Japan, US, RoW
Tarlatamab, AMG 757
Amgen
Neuroendocrine Prostate Cancer
07/24
07/24
NCT04885998: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Completed
1
23
Europe, Japan, US, RoW
Tarlatamab, AMG 757, AMG 404
Amgen
Small Cell Lung Cancer
07/23
09/24
PanTumor-101, NCT06551142 / 2024-513663-10-01: A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

Recruiting
1
845
Europe, Canada, Japan, US, RoW
Ris-Rez, Cisplatin, Carboplatin, Atezolizumab, Pembrolizumab, Durvalumab, Cetuximab, Bevacizumab, Tarlatamab, Dostarlimab
GlaxoSmithKline
Neoplasms
10/28
06/29
DeLLphi-308, NCT06598306 / 2024-511838-12-00: Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer

Recruiting
1
220
Europe, Japan, US, RoW
Tarlatamab, AMG 757, Imdelltra
Amgen, BeOne Medicines
Extensive Stage Small Cell Lung Cancer
03/27
04/30
DeLLphi-300, NCT03319940 / 2023-506541-39-00: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Active, not recruiting
1
269
Europe, Japan, US, RoW
Tarlatamab, Pembrolizumab, CRS Mitigation Strategies
Amgen
Small Cell Lung Cancer
12/26
12/27
DeLLphi-310, NCT06898957 / 2024-515903-21-00: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Active, not recruiting
1
29
Europe, Canada, US, RoW
YL201, Tarlatamab, Durvalumab
Amgen, MediLink
Small Cell Lung Cancer
06/31
06/31
20200040, 2024-513316-10-00: A Phase 1b Study of AMG 757 in Subjects with Neuroendocrine Prostate Cancer

Completed
1
11
Europe
Amgen Inc.
Adult subjects with de novo or treatment-emergent neuroendocrine prostate cancer
 
 
DeLLphi-311, NCT07037758: A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer

Recruiting
1
380
US, RoW
Tarlatamab, AMG 757, Imdelltra, AB248
Amgen, Asher Biotherapeutics, Inc.
Extensive Stage Small Cell Lung Cancer
03/28
01/31
DeLLphi-303, NCT05361395 / 2024-511021-58-00: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting
1
184
Europe, Canada, Japan, US, RoW
Tarlatamab, AMG 757, Carboplatin, Etoposide, Atezolizumab, Tecentriq, Durvalumab
Amgen
Extensive Stage Small Cell Lung Cancer
08/28
08/28
20160323, 2023-506541-39-00: A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)

Active, not recruiting
1
118
Europe
Amgen Inc.
Small Cell Lung Cancer
 
 
20200469, 2024-511021-58-00: First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer (ES SCLC) (DeLLphi-303)

Active, not recruiting
1
80
Europe
Amgen Inc.
Extensive Stage Small cell lung cancer (ES-SCLC)
 
 
20230298, 2024-511838-12-00: Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Recruiting
1
34
Europe
Amgen Inc.
Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
 
 
20240124, 2024-515903-21-00: Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)

Recruiting
1
47
Europe
Amgen Inc.
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
 
 
DeLLphi-313, NCT07531095 / 2025-522888-15-00: Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

Recruiting
1
160
US, RoW
ZL-1310, Tarlatamab, IMDELLTRA, Durvalumab
Amgen
Small Cell Lung Cancer
05/28
05/31
NCT06957314: A Study of Hospital-at-Home for People Receiving Tarlatamab

Recruiting
N/A
70
US
Hospital-at-Home/HAH
Memorial Sloan Kettering Cancer Center
Small-cell Lung Cancer, Small Cell Lung Carcinoma
04/28
04/28
NCT07468656: SCLC Tarlatamab Blood Collection

Not yet recruiting
N/A
25
NA
Duke University
Small-cell Lung Cancer
12/28
12/28

Download Options